#USA #Center Valley #Olympus #EndoTherapy #W. L. Gore

Olympus and W. L. Gore Join Forces to Revolutionize EndoTherapy

Olympus Corporation, recognized globally for its commitment to enhancing health and safety through innovative MedTech solutions, has recently announced a strategic international distribution agreement with W. L. Gore & Associates, a pioneer in material science and innovative product development across various industries. This collaboration marks a significant step towards broadening Olympus's EndoTherapy product offerings, particularly through the exclusive distribution rights for the GORE® VIABIL® Biliary Endoprosthesis.

Strategic Expansion in MedTech

The agreement establishes Olympus as the exclusive international distributor of this advanced biliary endoprosthesis for endoscopic applications. The commercialization of this new device is set to begin in Europe, with plans to gradually extend to other global markets.

By incorporating the GORE® VIABIL® Biliary Endoprosthesis into its hepatopancreatobiliary (HBP) portfolio, Olympus aims to significantly strengthen its presence in the rapidly evolving gastrointestinal (GI) metal stent market. The device addresses critical needs associated with biliary strictures, providing healthcare professionals with an innovative solution to improve patient outcomes.

Enhanced Patient Care Through Innovation

Both Olympus and Gore share a rich history of delivering cutting-edge interventional therapeutic products aimed at elevating the standard of care. The collaboration is anticipated to enhance the comprehensive range of GI devices available to healthcare providers and their patients.

The GORE® VIABIL® Biliary Endoprosthesis is a remarkable fully covered self-expanding metal stent that offers a new alternative for alleviating symptoms related to biliary strictures. Key features of this endoprosthesis include:

• - Non-Foreshortening Design: Specifically engineered to maintain accurate deployment positioning, thereby minimizing potential complications associated with other stents.
• - Durable Barrier: The device is lined with nonporous ePTFE/FEP (expanded polytetrafluoroethylene/fluorinated ethylene propylene), which acts as a robust barrier to prevent tumor ingrowth without elevating the migration rates often seen with covered stents.

Mike Callaghan, Global Senior Vice President and General Manager of EndoTherapy at Olympus, expressed enthusiasm about the partnership, stating, "We are thrilled to collaborate with Gore, a global leader in innovative technologies. The VIABIL stent is a critical device for GI patient care, and this agreement will complement our industry-leading ERCP portfolio."

Jake Goble, Cardiac and Surgical Solutions Business Leader at Gore, added, "We strongly believe the demonstrated commercial prowess of Olympus' EndoTherapy team will pair nicely with Gore's medical device innovation expertise to better serve patients with unique solutions for many years to come."

Commitment to Healthcare Advancement

Olympus has been dedicated to making lives healthier, safer, and more fulfilled for over a century. Their focus on strategic partnerships reflects their commitment to innovation in early detection, diagnosis, and minimally invasive treatment. The collaboration with Gore is a key milestone in Olympus's mission to partner with healthcare professionals and provide solutions that enhance patient care and outcomes.

In conclusion, this partnership between Olympus Corporation and W. L. Gore & Associates is poised to redefine standards in the biliary treatment landscape, showcasing how innovative collaboration can lead to significant improvements in healthcare delivery on a global scale.

For more information about Olympus and its commitment to improving patient outcomes, visit olympus-global.com.